National Cancer Institute (NCI)

United States

3 Trials

The National Cancer Institute (NCI) is the principal US federal agency for cancer research and training, one of 27 institutes within the National Institutes of Health, with an annual budget exceeding $7 billion. In the psychedelic field, NCI has supported trials exploring psilocybin-assisted therapy for cancer-related demoralization and chronic pain in survivors, as well as ketamine infusion to prevent depression in patients undergoing treatment for pancreatic and head-and-neck cancers.

Foundations & Philanthropy Snapshot

Grant-Making Organizations

Classification

Public Charity / Non-Profit

Geography

Global

Coverage

Global

Last Verified

Apr 10, 2026

Funding Focus Areas

Academic Research FundingClinical Trial Funding

Support Types

Grant Funding

Philanthropy Notes

Auto-backfilled baseline philanthropy profile from existing category tags and website. Manual enrichment recommended for recipient-level details.

Verification

Verified

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement Status

Active

Verification Notes

Verified against official NCI grants and research training pages.

Primary Funding Link

Source Evidence

National Cancer Institute (NCI) website

https://www.cancer.gov

NCI Home

https://www.cancer.gov

NCI Grants & Training

https://www.cancer.gov/grants-training

Quick Facts

Type: Other
HQ: United States
Website: Visit

Collaborated Trials

RecruitingII, III

Psilocybin Therapy in Advanced Cancer

Start Date: November 1, 2022
Compounds: Psilocybin, Placebo

CompletedI

Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain

Start Date: August 31, 2022
Compounds: Psilocybin

WithdrawnI

Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers

Start Date: August 15, 2016
Compounds: Ketamine, Placebo